Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: Potential benefits of calcitriol

J Allergy Clin Immunol. 2015 Sep;136(3):628-637.e4. doi: 10.1016/j.jaci.2015.01.026. Epub 2015 Mar 13.

Abstract

Background: A small population of patients with severe asthma does not respond to glucocorticoids (steroid resistant [SR]). They have high morbidity, highlighting an urgent need for strategies to enhance glucocorticoid responsiveness.

Objective: We investigated the immunologic differences between steroid-sensitive (SS) and SR asthmatic patients and the effect on immunophenotype of oral calcitriol treatment because it has been previously shown to beneficially modulate the clinical response to glucocorticoids in patients with SR asthma.

Methods: CD8-depleted PBMCs were isolated from 12 patients with SS and 23 patients with SR asthma and cultured for 7 days with anti-CD3 and IL-2 with or without dexamethasone. Cytokine production was assessed in supernatants by using the Cytometric Bead Array. Patients with SR asthma were subsequently randomized to oral calcitriol or placebo therapy, and identical studies were repeated.

Results: Patients with SR asthma produced significantly increased IL-17A and IFN-γ levels compared with those in patients with SS asthma, although it was evident that cells from individual patients might overproduce one or the other of these cytokines. Production of IL-17A was inversely and production of IL-13 was positively associated with the clinical response to prednisolone. Oral calcitriol, compared with placebo, therapy of the patients with SR asthma significantly improved dexamethasone-induced IL-10 production in vitro while suppressing dexamethasone-induced IL-17A production. This effect mirrored the previously demonstrated improvement in clinical response to oral glucocorticoids in calcitriol-treated patients with SR asthma.

Conclusions: IL-17A(high) and IFN-γ(high) immunophenotypes exist in patients with SR asthma. These data identify immunologic pathways that likely underpin the beneficial clinical effects of calcitriol in patients with SR asthma by directing the SR cytokine profile toward a more SS immune phenotype, suggesting strategies for identifying vitamin D responder immunophenotypes.

Keywords: Asthma; IL-17A; glucocorticoids; steroid resistant; steroid sensitive; vitamin D.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / pharmacology
  • Adult
  • Asthma / drug therapy*
  • Asthma / immunology
  • Asthma / pathology
  • CD3 Complex / pharmacology
  • Calcitriol / therapeutic use*
  • Dexamethasone / pharmacology
  • Drug Resistance
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Immunophenotyping
  • Interferon-gamma / biosynthesis*
  • Interferon-gamma / immunology
  • Interleukin-10 / biosynthesis
  • Interleukin-10 / immunology
  • Interleukin-17 / biosynthesis*
  • Interleukin-17 / immunology
  • Interleukin-2 / pharmacology
  • Leukocytes, Mononuclear / drug effects*
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / pathology
  • Male
  • Middle Aged
  • Prednisolone / therapeutic use*
  • Primary Cell Culture
  • Severity of Illness Index

Substances

  • Adrenal Cortex Hormones
  • CD3 Complex
  • IL10 protein, human
  • IL17A protein, human
  • Immunologic Factors
  • Interleukin-17
  • Interleukin-2
  • Interleukin-10
  • Dexamethasone
  • Interferon-gamma
  • Prednisolone
  • Calcitriol